Search Results
Gilteritinib
Gilteritinib is a indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Brexucabtagene autoleucel
Brexucabtagene autoleucel is FDA approved for the treatment of
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL).
This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Filgrastim
Filgrastim is FDA approved to
Why our health equity grants are more important than ever before
For 40 years, I’ve poured my life into fighting cancer. Working alongside doctors, nurses, social workers, researchers—and of course patients and their loved ones—we’ve made incredible progress.
But what keeps me up at night after all these years is the realization that, for too long, the health sector didn’t focus on the holes in that progress. As we collectively sprinted towards better treatments, we’ve left some patients behind.
Nutrition Advice from a Dietitian & Blood Cancer Survivor
76-year-old Barbara Borrell is a woman who wears many hats – a 50+ year registered dietitian, nutrition consultant and educator, cancer advocate, volunteer with The Leukemia & Lymphoma Society, and a blood cancer survivor who has battled not one, not two, but three types of blood cancer.
Heart Disease in Lymphoma Survivors
Matthew Matasar is a hematology and oncology specialist at Memorial Sloan-Kettering Cancer Center in New York City. He has a Translational Research Program grant through The Leukemia & Lymphoma Society and is investigating which Hodgkin lymphoma survivors are at greater risk for developing heart disease after receiving radiation therapy to the chest and what diagnostic tests are best.
Sargramostim
Sargramostim is FDA approved
Tisagenlecleucel
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of
RESEARCH NOW: 9/11 AND BLOOD CANCER RISK IN FIRST RESPONDERS
All of us were impacted by the tragedy of September 11. For those who dedicated countless hours to rescue, recovery, and clean-up efforts, the effects of that devastating incident continue to be a challenge. Firefighters, police officers, emergency medics and others were exposed to harmful fumes and dust in the weeks and months following that disaster.
Lisocabtagene maraleucel
Lisocabtagene maraleucel is indicated for the treatment of
5 Ways to Support Blood Cancer Patients
Have you ever Googled, “what to do for someone with cancer”?
Have you felt helpless or frustrated when trying to think of something meaningful to offer them or do for them? You want them to know you’re ready to help, but don’t know how to help.
We’re often told to just ask the person what they need. But the truth is, they probably don’t know what they need. And figuring it out can be tough on top of all the new questions that come with their diagnosis.
So now what?
One Family’s Inspiring Quest to Help Other Families Impacted By Cancer
A nasty cough and extreme fatigue first led Myrna and Lou Binder to bring their 12-year-old son, Jeff, to the doctor for an examination. But the flu-like symptoms persisted until more tests enabled the doctors to arrive at the shocking diagnosis: non-Hodgkin lymphoma. The year was 1975.